Case Studies

Summary Interstitial lung disease (ILD) emerged as a potential safety signal within a multi‑cohort antibody–drug conjugate (ADC) oncology program. Recognizing this need early in development, the sponsor study team sought…

Overview A global biopharmaceutical company conducting a pivotal oncology trial encountered significant imaging challenges that put the study’s progress and secondary endpoint integrity at risk. Because the trial required specialized…